Endocarditis antithrombotic therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(/* Antithrombotic Therapy{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C.,...) |
||
| Line 6: | Line 6: | ||
==Antithrombotic Therapy<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref>== | ==Antithrombotic Therapy<ref name= Baddour>{{cite journal | author = Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A.| title = Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America. | journal = Circulation | volume = 111 | issue = 23 | pages = 3167-84 | year = 2005 | id = PMID 15956145 }}</ref>== | ||
* [[Anticoagulant]]s can cause or worsen hemorrhage in patients with [[endocarditis]] but may be carefully administered when needed | * [[Anticoagulant]]s can cause or worsen hemorrhage in patients with [[endocarditis]] but may be carefully administered when needed. | ||
* The [[prothrombin time]] should be carefully maintained at an INR of 2.0–3.0 | * The [[prothrombin time]] should be carefully maintained at an INR of 2.0–3.0. | ||
* Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 wk after an acute embolic stroke | * Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 wk after an acute embolic stroke. | ||
* Avoid [[heparin]] administration during active [[endocarditis]] if possible | * Avoid [[heparin]] administration during active [[endocarditis]] if possible. | ||
==References== | ==References== | ||
Revision as of 00:10, 16 December 2012
|
Endocarditis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease |
|
Case Studies |
|
Endocarditis antithrombotic therapy On the Web |
|
Risk calculators and risk factors for Endocarditis antithrombotic therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Antithrombotic Therapy[1]
- Anticoagulants can cause or worsen hemorrhage in patients with endocarditis but may be carefully administered when needed.
- The prothrombin time should be carefully maintained at an INR of 2.0–3.0.
- Anticoagulation should be reversed immediately in the event of CNS complications and interrupted for 1–2 wk after an acute embolic stroke.
- Avoid heparin administration during active endocarditis if possible.
References
- ↑ Baddour Larry M., Wilson Walter R., Bayer Arnold S., Fowler Vance G. Jr, Bolger Ann F., Levison Matthew E., Ferrieri Patricia, Gerber Michael A., Tani Lloyd Y., Gewitz Michael H., Tong David C., Steckelberg James M., Baltimore Robert S., Shulman Stanford T., Burns Jane C., Falace Donald A., Newburger Jane W., Pallasch Thomas J., Takahashi Masato, Taubert Kathryn A. (2005). "Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association-Executive Summary: Endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): 3167–84. PMID 15956145.